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Purpose: Retrospective r views uggest that the progression of peripheral vascular disease 
(PVD) may be accelerated in heart transplant recipients. This study was undertaken to 
determine the incidence and to identify those risk factors that may be associated with the 
development or progression of PVD in these patients. 
Methods: Between January 1990 and December 1993 a prospective vascular screening 
protocol including abdominal ultrasonography, Doppler-derived ankle-brachial pressure 
indexes (ABI), and carotid artery duplex imaging was added to the routine preoperative 
and annual postoperative evaluation of 239 heart ransplant recipients. 
Results: Thirty-one significant vascular lesions were detected in 10% (24 of 239) of patients 
52 --. 9 years of age at a mean of 3.2 years after transplant. The distribution of lesions 
included carotid artery stenosis (11), femoropopliteal occlusive disease (10), aortoiliac 
occlusive disease (five), aortic aneurysm (four), and renal artery stenosis in one patient. 
Revascularization procedures were performed in 12 (50%) patients (carotid endarterec- 
tomy (four), aortobifemoral bypass grafting (three), abdominal aortic aneurysm repair 
(two), transluminal ngioplasty (two), splenorenal bypass (one), and femorotibial bypass 
grafting (one)). One patient with diabetes mellitus (DM) was found to have noncom- 
pressible vessels during pretransplant evaluation. An additional 26 patients (11%), seven 
with DM, had noncompressible v ssels in the lower extremities during the follow-up 
period. Logistic regression analysis revealed that the development of posttransplant PVD 
was associated with smoking (p < 0.05) and ischemic ardiomyopathy as an indication for 
transplantation (p < 0.05). The development of noncompressible vessels was associated 
with younger age (p < 0.05) and the presence of diabetes (p < 0.05). 
Conclusion: Post'transplant peripheral vascular disease occurred in 10% of heart ransplant 
recipients and is associated with pretransplant ischemic ardiomyopathy and smoking. A 
previously unrecognized subgroup of patients who have noncompressible v ssels after 
operation is described. If the long-term survival of the heart ransplant recipient is to be 
improved, routine follow-up to identify and treat those patients at greater isk appears 
justified. (J VASC SURG 1995;22:434-42.) 
Recent advances in immunosuppressive regimens 
have increased the survival of patients undergoing 
heart ransplantation. One-year patient survival rates 
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range from 85% to 94%. 1,2 Long-term survival, 
however, despite the introduction ofcyclosporin and 
the use of antiplatelet drugs, is limited by the 
development of accelerated coronary atherosclerosis 
(ACAS), demonstrable with angiographic evaluation 
in 14%, 37%, and 50% of patients at 1, 3, and 5 
years, respectively, a,4
A number of risk factors including indications for 
transplantation, donor age, cytomegalovirus infec- 
tion, chronic cellular rejection episodes, humoral 
rejection, and the persistence of pretransplant risk 
factors for atherosclerosis have all been implicated in 
the development of ACAS. 3qa A well-known asso- 
ciation exists between peripheral vascular disease 
(PVD) and coronary artery disease (CAD). Newman 
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et al. 14 have demonstrated a 33% incidence of angina 
and congestive heart failure in patients with an ABI 
of <0.8. Follow-up studies of patients with inter- 
mittent daudication have demonstrated a 10-year 
decrease in life expectancy, predominately caused by 
premature cardiovascular disease. 1S The hypothesis 
of this study was that the adverse ffects of immu- 
nosuppressive therapy on lipoproteins in combina- 
tion with coexistent risk factors would facilitate the 
development and progression of PVD in heart 
transplant recipients. 
This prospective study was undertaken to deter- 
mine the incidence of PVD and to identify those 
patients who might be at greater risk for development 
of PVD after transplantation. I  addition, we de- 
scribe a subgroup of 27 patients who had noncom- 
pressible vessels in the posttransplant period. 
PATIENTS AND METHODS 
As of December 1993, 239 heart transplant 
recipients have been evaluated in our noninvasive 
vascular laboratory. 
Patients were examined before transplantation 
and annually thereafter. Each yearly evaluation in- 
cluded a history and physical examination, routine 
blood-chemistry measurements, evaluation of medi- 
cation use, and an assessment of risk factors for 
atherosclerosis. 
Hypercholesterolemia or hypertriglyceridemia 
were diagnosed if the serum cholesterol r triglycer- 
ide concentrations exceeded 250 mg/dl. Reference 
ranges for lipid profiles at the University of Arizona 
Health Sciences Center include 150 to 210 mg/dl 
cholesterol, 50 to 160 mg/dl triglycerides, >45 
mg/dl high-density lipoprotein (HDL), and < 120 
mg/dl low-density lipoprotein (LDL). Hyperlipid- 
emia was treated with nicotinic acid, lovastatin, and 
gemfibrizol. Hypertension was defined as a blood 
pressure of _ 140/90, or treatment for hyperten- 
sion. Calcium channel blockers and angiotensin-con- 
verting enzyme inhibitors either alone or in combina- 
tion were the drugs most commonly used to control 
blood pressure. 
The extent of coronary artery disease was assessed 
by coronary angiography and MUGA scans. Periph- 
eral vascular disease was evaluated with abdominal 
ultrasonography. Doppler-derived resting ABIs, and 
carotid artery duplex imaging. The vessels of patients 
with suspected PVD were further evaluated with du- 
plex imaging, resting and exercise segmental pressure 
measurements, and arteriography as indicated. 
A resting ABI of less than 0.9 or a diminution of 
_ 0.2 were considered indicative of peripheral vas- 
cular disease. Vessels with an ABI _> 1.4 were 
regarded as noncompressible. Carotid artery stenosis 
_> 50% by duplex scanning with evidence of plaque 
on grey scale imaging was regarded as significant. 
Normal studies in patients with a history of treatment 
for vascular disease were also noted. No patient with 
known evidence of peripheral vascular disease under- 
went transplantation. The evaluation and analysis of 
patients with abdominal aortic aneurysms has been 
described previously and will not be addressed. 2,16 
All patients were treated with a triple-drug 
regimen of cyclosporin, prednisone, and Imuran. 
Prednisone dosage was rapidly tapered to between 5
to 10 rag/day. No patient reated with Imuran and 
prednisone alone was included in the analysis. 
Statistical methods. Data are expressed as the 
mean _+ standard eviation. Differences between the 
groups before transplant and during the study were 
assessed with chi-square analysis for nonparametric 
data and with the paired t test for parametric data. 
The relationships between the groups were deter- 
mined with ANOVA. Logistic regression was per- 
formed with the method of Neter.17 All analyses were 
carried out with SPSS or SAS software (SAS 
Institute, Cary, N.C.). 
RESULTS 
Two hundred thirty-nine heart ransplant recipi- 
ents, 194 (81%) men and 45 (19%) women ranging 
in age from 16 to 69 years (mean 49 _+ 11 years), 
underwent prospective follow-up for a mean of 38.8 
months (range 1 to 155 months). 
Of these, 128 (54%) received transplants during 
the study interval, and the remaining 111 (46%) 
received transplants before 1990. All patients had 
pretransplant screening studies performed, even if the 
transplantation was performed before the institution 
of the prospective protocol. The indications for 
transplantation were ischemic (47.4%), idiopathic 
(29.5%), and viral (5.1%) cardiomyopathy. Valvular 
disease (4%) and miscellaneous congenital heart 
lesions (14%) composed the remainder. 
Eighteen (6%) patients died as a result of 
rejection, intracranial hemorrhage, infection, or ma- 
lignancy during the study period. No deaths were 
attributable to peripheral vascular disease. 
No significant differences were seen between 
groups regarding the incidence of risk factors with 
the exception of a greater number of smokers among 
patients receiving transplants for ischemic ardiomy- 
opathy. Cholesterol and triglyceride levels were 
elevated in most patients after they received their 
transplants (Table 1). A trend toward higher triglyc- 
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Table I. Comparison between pretransplant and posttransplant lipid levels in heart ransplant 
recipients with and without PVD 
No PVD PVD 
Before operation 3 years Before operation 3 years 
Cholesterol (mg/dl) 190 _+ 54 254 + 54 ~ 136 -+ 52 301 -+ 92 * 
Triglyceride (mg/dl) 201 _+ 222 296 + 286 118 +- 39 499 + 650 ~ 
HDL Cholesterol (mg/dl) 32 -- 8 42 _+ 15 58 -+ 36 71 +- 46 ~ 
LDL Cholesterol (mg/dl) 129 _+ 36 153 +_ 33 104 --+- 20 132 _+ 56 
~p < 0.05. Note: p < 0.05 preoperative versus postoperative, butp  
Table II. Distribution of vascular lesions in 
heart ransplant recipients 
No. 
Carotid artery stenosis 5 
Femoropopliteal Disease 5 
Aortoiliac Disease 4 
Abdominal aortic aneurysms 3 
Femoropopliteal + carotid artery stenosis 4 
Femoropopliteal + aortoiliac disease I 
Renal + carotid artery stenosis 1 
Aortic aneurysm + carotid artery stenosis 1 
eride levels was seen in the transplant recipient who 
had PVD compared with those who did not have 
PVD, but this trend did not reach statistical signifi- 
cance. Although patients with PVD were older 
(52 + 9 versus 48 + 11 years) than those without 
PVD, this difference did not achieve statistical 
significance. All transplant recipients demonstrated 
an increase in weight after transplantation. At 3 years 
weight increased from 72 + 17 kg to 81 + 21 kg in 
patients without PVD and from 72 + 13 kg to 
87 _+ 4 kg in the group with PVD (p = NS). 
Thirty-one peripheral vascular lesions were de- 
tected in 10% (24 of 239) of patients at a mean of 3.2 
years after transplantation (range 1 to 7 years). Seven 
(29%) of the 24 patients had involvement at two 
sites. The distribution of peripheral vascular lesions 
are fisted in Table II. 
Noncompressible lower extremity vessels were 
observed in 27 (11%) transplant recipients, eight 
(30%) of whom had diabetes. Only one patient with 
DM had noncompressible vessels before transplanta- 
tion (ABI of 1.4 bilaterally). 
Four patients, two with diabetes, had noncom- 
pressible vessels and evidence of peripheral vascular 
disease. Two of these patients had infralnguinal 
ischemia, one had an abdominal ortic aneurysm, and 
the remaining patient had both renal and carotid 
artery stenosis. 
Twenty percent (47 of 239) of all transplant 
= NS between groups. 
recipients and 29% (7 of 24) of patients with PVD 
had ACAS. 
In a stepwise logistic regression analysis of 
potential risk factors for the development of PVD 
after transplantation, only smoking (p < 0.05) and 
ischemic ardiomyopathy (p < 0.02), when mod- 
eled as an independent variable, were significantly 
related to the development ofPVD. Although most 
of the patients had a significant increase in both 
cholesterol and triglyceride l vels after transplanta- 
tion, no significant differences were seen in lipid 
levels between patients who did and those who did 
not have PVD. 
Similarly, stepwise logistic regression analysis of 
risk factors in the group of patients with noncom- 
pressible vessels demonstrated an association be- 
tween a younger age at the time of transplantation 
(p < 0.05) and the presence of diabetes (p < 0.05) 
(Table III). 
Therapeutic procedures. Fourteen revascular- 
ization procedures were performed in 12 patients 
who had PVD. These included carotid endarterec- 
tomy (four), aortobifemoral grafting (three), ab- 
dominal aortic aneurysm repair (two), transluminal 
angioplasty (two), splenorenal bypass (one), femo- 
rotibial (one), and femoro-femoral (one) bypass 
grafting. One patient underwent both aortobifemo- 
ral and femoral tibial bypass grafting, and another 
had a carotid endarterectomy and a splenorenal 
bypass. All surgical and radiologic interventions were 
performed by use of standard indications for vascular 
surgery. Of the six carotid endarterectomies, four 
were for hemispheric symptoms and two for high- 
grade asymptomatic stenosis found by screening. The 
aortic aneurysms were detected with screening ultra- 
sonography and were resected when they reached 
5 cm. All bypasses or interventions for occlusive 
disease were needed for severe claudication or Limb 
salvage. Both renal artery procedures were performed 
for severe hypertension and renal dysfunction with 
high-grade renal artery stenoses. 
Pathologic findings. All plaques removed at 
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Table III. Demographics and risk factors 
of patients with compressible and 
noncompressible vessels at 3 years 
Compressible Noncompressible 
vessels vessels 
(n = 212) (n = 27) 
Age (yrs) 49 _+ 10 46 ± 6* 
Sex 167 males (79%) 24 males (89%) 
Diabetes 31 (17%) 8 (30%)* 
Hypertension 104 (49%) 16 (59) 
Smoking 19 (9%) 3 ( I I%) 
Cholesterol 254 _+ 286 224 -+ 60 
(mg/dl) 
Triglyceride 296 ± 286 199 ± 100 
(mg/dl) 
HDL Cholesterol 42 ± 15 44 -+ 8 
(mg/dl) 
LDL Cholesterol 156 -+ 33 172 ± 67 
(mg/dl) 
~p < 0.05 determined via logistic regression modeling. 
surgery were examined intact and by light micros- 
copy and demonstrated surface thrombus, ulceration, 
and medial calcification, which is characteristic of
complex atherosclerotic plaque in patients who do 
not receive transplants. 
DISCUSSION 
The cause of arterial occlusive lesions in the lower 
extremities of patients being evaluated for heart 
transplantation varies considerably. In addition to the 
presence of risk factors for atherosclerosis, these 
patients have typically undergone multiple cannula- 
tions of their vessels for diagnostic and therapeutic 
interventions) 8 Moreover, patients with dilated car- 
diomyopathy and valvular heart disease are at risk for 
distal embolization. As a result, patients being 
evaluated for heart ransplantation ften have clinical 
or diagnostic evidence of preexisting peripheral 
vascular disease. Because of the known adverse ffects 
of both cyclosporin and prednisone on lipoproteins 
and blood pressure in addition to the prothrombotic 
effects of cyclosporin, patients with known symp- 
tomatic or significant asymptomatic peripheral vas- 
cular disease are usually excluded from consideration 
for transplantation. ~9 
Ten percent of heart ransplant recipients in this 
study had peripheral vascular disease at a mean 
interval of 3.2 years after transplantation. Carotid 
artery stenosis and femoropopliteal/tibial occlusive 
disease alone or together were the most common 
vascular lesions observed. This incidence issimilar to 
that in previously published retrospective studies 
reported by Bull et al. (10%) 20 and Julia et al. 
(9.9%) 21 in heart ransplant recipients and to that in 
the study by Vathsala et al. (9.4%) 22 in kidney 
transplant recipients treated with cyclosporin and 
prednisone. Benvenisty 18found a 5% incidence of 
PVD in adult patients after heart transplantation; 
however, a rigorous follow-up protocol was not used 
in their patients. Both the studies of Julia et al. and 
Benvenisty et al. included a significant number of 
patients known to have PVD before transplanta- 
tion) 8m Furthermore Julia et al. suggest that post- 
transplant PVD is merely acontinuum of preexisting 
atherosclerosis and that the natural progression of 
atherosclerosis is not influenced by transplantation.2 
In this study only patients without discernable 
vascular disease were considered for transplantation. 
Therefore any lesions that became evident after 
transplantation most likely represent acceleration of
plaque formation, which occurs 10 to 1 5 years earlier 
than in the general population who have atheroscle- 
rosis. Color-flow duplex imaging and intravascular 
ultrasonography ave recently been used in heart 
transplant recipients. 4,23 These relatively new imag- 
ing modalities may permit recognition of the char- 
acteristic features of early plaque in the coronary and 
peripheral vessels and more accurate assessment of
the natural history of plaque formation in patients 
with CAD and PVD. 
The identification of those risk factors that may 
enhance progression of atherosclerotic plaque in 
transplant recipients remains unclear. Bull et al.~6 
reported that a pretransplant history of ischemic 
cardiomyopathy, post-transplant hypertension, and 
posttransplant hypertriglycefidemia were the only 
risk factors predictive of the development of PVD 
after heart ransplantation. I  contrast, Julia et al.21 
found that ischemic heart disease and hypercholes- 
terolemia were related to the prevalence of PVD. 
Although cholesterol concentrations were signifi- 
cantly higher at 3 years after transplantation when 
compared with pretransplant levels in all the patients 
in our study, no significant differences were seen in 
cholesterol levels between patients with and without 
PVD. Serum triglyceride concentrations were higher 
at 3 years than pretransplant levels in patients with 
PVD; however, this finding did not reach statistical 
significance in the regression model. It is our 
supposition based on the previous retrospective 
review and the trend noted in this prospective study 
that with more patients and longer follow-up, 
hypertriglyceridemia will prove to be a significant risk 
factor for the development of PVD in heart trans- 
plant recipients. An unexpected observation was an 
elevation in HDL cholesterol in patients with PVD. 
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The importance of this observation eeds further 
investigation. 
Both heart and kidney transplant recipients re- 
ceiving immunosuppression with cyclosporin and 
prednisone (CS-P) have been demonstrated to have 
increased levels of cholesterol and triglycerides.22,24-29 
Between 16% and 78% of renal transplant recipients 
treated with azathioprine and prednisone (AZ-P) 
have hypercholesterolemia or hypertriglyceridemia 
within 4 to 10 months of transplantation. 3° These 
changes in lipid profiles are believed to be related to 
the effects of prednisone on hepatic lipid synthesis. 
Vathsala et al. 22 reported a similar incidence of 
hypercholesterolemia in large cohort of patients 
treated with CS-P. It has been estimated that more 
than 80% of heart ransplant recipients treated with 
CS-P have elevated cholesterol levels. Hypercholes- 
terolemia fter transplantation is reported to occur 
more commonly in patients who have hyperlipi- 
demia before transplantation, i  older individuals, 
and in those patients undergoing transplantation for
CAD. 2r,28 Kidney transplant recipients treated with 
cyclosporin have reduced prednisone requirements, 
fewer ejection episodes, and a 15% to 20% increase 
in cholesterol and triglyceride l vels compared with 
patients receiving conventional therapy with AZ-P. 24 
In addition to its effects on lipids, cyclosporin has also 
been shown to increase the risk of venous throm- 
boembolism and is associated with intravascular 
coagulation, which may further contribute to vascu- 
lar symptoms, s°m 
Numerous attempts have been made to reduce or 
eliminate prednisone from immunosuppressive regi- 
mens because of its known effects on hepatic 
lipogenesis in addition to its other well-recognized 
complications. In cardiac transplant recipients pred- 
nisone predisposes to weight gain and glucose 
intolerance and also contributes to the elevation of 
triglycerides, LDL, and total cholesterol, ag,ss The 
contribution of steroids to the development of PVD 
in heart ransplant recipients i difficult o evaluate, 
because the mean daily steroid dose at 3 years was 
only 6.8 mg. This, however, does not take into 
account the effects of higher steroid doses adminis- 
tered during the early postoperative p riod and the 
bolus therapy used to treat rejection episodes. The 
treatment of hypercholesterolemia in transplant re- 
cipients receiving cyclosporin is complicated by the 
known interaction between HMG CoA reductase 
inhibitors and cyclosporin. Rhabdomyolysis of vary- 
ing severity is an uncommon but serious complica- 
tion of the use of HMG CoA reductase inhibitors in 
combination with cyclosporin therapy. 34 Recently 
Kobishigawa et al. 32 reported a 28% reduction in 
cholesterol levels with low-dose Lovastatin therapy 
(20 mg/day) and recommended that enzyme inhibi- 
tor levels be monitored to enhance safe administra- 
tion of this drug in heart ransplant recipients. 
In this study cigarette smoking and ischemic 
cardiomyopathy were the only two risk factors 
predictive for PVD. Although each of our patients is 
encouraged to stop smoking, a significant number 
continue or recommence smoking in the follow-up 
period. Smoking was not found to be a significant 
risk factor in the development of PVD in our 
previous retrospective study. 2° Because patients who 
smoke cigarettes may not be considered as favorably 
as nonsmokers for transplantation, many patients 
deny any substantial smoking history. In this study a 
more thorough smoking history was elicited, which 
probably explains its greater prevalence. 
Twenty-seven patients were found to have non- 
compressible vessels in the posttransplant period. 
Noncompressible v ssels are characteristically found 
in patients with DM; however, only eight of the 27 
patients had or eventually had development of DM, 
and 26 of the 27 patients had normal ABIs before 
operation. Whether noncompressible v ssels are a 
marker of latent diabetes or a complication of 
immunosuppressive th rapy is presently unknown. 
The observation that calcium channel blockers may 
limit the progression of ACAS lends credence to the 
possible role of calcium in the cause of noncompress- 
ible vessels. 12 Whether the beneficial effects of 
calcium channel blockers in patients with ACAS is 
due to calcium-dependent mechanisms or to an 
immune suppressive ffect is under investigation. 
Four of the patients with noncompressible v ssels 
also had PVD, suggesting that the pathogenesis of
these two conditions may be related. 
No significant correlation was seen between 
ACAS and the development of peripheral vascular 
disease. This study confirms our previous findings of 
an overlap in the risk factors between peripheral 
vascular disease and ACAS but does not show a 
significant correlation between them) 6
Heart transplant recipients undergoing vascular 
procedures have an altered hemodynamic response to 
operation. The intraoperative treatment of these 
patients has been discussed by Piotrowski et al. 2 We 
have encountered no unusual technical difficulties 
when operating on these patients. 
The 10% incidence of peripheral vascular disease 
and the 11% incidence of noncompressible v ssels 
suggests the need for ongoing vascular laboratory 
follow-up of these patients with noninvasive vascular 
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testing. However, the cost of routine follow-up of all 
patients ignificantly increases the annual cost of heart 
transplantation. One of the objectives of this study 
was to identify those patients who would benefit 
most from continued follow-up and to devise a more 
selective approach for the evaluation of these patients. 
The marked variation in incidence of risk factors 
makes selection of those patients requiring more in- 
tensive follow-up difficult. However, based on the 
results of this study and the abundance of evidence 
implicating hyperlipidemia in plaque formation, we 
believe that patients who have ischemic ardiomyop- 
athy as an indication for transplantation, who con- 
tinue to smoke, or who have uncontrolled hyperlip- 
idemia should undergo follow-up at yearly intervals. 
Because neither the cause nor clinical significance of 
noncompressiblc vessels is fully understood, contin- 
ued follow-up of these patients, once identified, 
seems prudent. Because ACAS significantly reduces 
the life expectancy of heart transplant recipients,14 the 
patients at greatest risk should undergo intensive risk 
factor reduction to improve long-term survival. 
In conclusion, the development of posttrans- 
plant vascular disease is a significant problem af- 
fecting 10% of transplant recipients within 3 years 
of transplantation. The development of noncom- 
pressible vessels after transplantation is a new ob- 
servation and may be related to the evolution of 
clinically apparent vascular disease. Detailed vascular 
laboratory follow-up may improve our understand- 
ing of the natural history of PVD in transplant 
recipients and identify those patients who would 
benefit most from risk factor reduction before severe 
complications ensue. 
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DISCUSSION 
Dr. R. Scott Mitchell (Stanford, Calif.). These 
authors focus our attention on the appearance of PVD in 
this heart transplant population. A total of 239 patients 
received heart transplants from the University of Arizona, 
and of these 128 received transplants during the study 
period. 
When a prospective screening protocol of carotid 
artery duplex scanning, abdominal ultrasonography, and 
Doppler-derived ankle/brachial indexes was used, al- 
though no patient was offered transplantation if there was 
evidence for PVD, it was not stated in the manuscript 
what exact exclusionary criteria were used. However, we 
did learn some more about the criteria for the carotid 
artery duplex scanning. 
During the mean follow-up interval of 38 months PVD 
developed in 10% of their patients, and an additional 11% 
had noncompressible v ssels. Only smoking and ischemic 
cardiomyopathy were independent risk factors for devel- 
opment in this regression analysis. Of these 24 patients, 
however, only 12 patients required revascularization pro- 
cedures, which raises my first question. How was the total 
extent of PVD in this population estimated? 
Some of my comments are directed from our own 
Stanford database, and I first apologize for its lack of 
completeness, especially with regard to PVD, particularly 
when compared with the Arizona database. Many of our 
patients are monitored separate from the university hospi- 
tal at their local hospitals, and we do not get to get all that 
data. However, for the last 11 to 14 years, we think our data 
on PVD is more complete, and most of my observations 
come from our database. 
I still would specify that of our 750 transplant patients 
now encompassing over 25 years, we identified only 13 
patients who had significant PVD, and of these, three had 
actually undergone peripheral vascular procedures before 
transplantation, meaning only 10 patients or slightly less 
than 2% had significant PVD in the posttransplant period. 
Now, the authors address the question of whether this 
is merely progression of preexistent disease or if, in fact, the 
transplant immunosuppression regimen exacerbates or 
rapidly accelerates PVD in this population. The group 
suggests that this is probably a rapid exacerbation, but the 
Stanford ata would take exception to that in that a number 
of our patients who had disease indeed had it before 
transplantation. 
Additionally, our patients were significantly older and 
had PVD at a significantly longer interval after transplan- 
tation at an average of 9.6 years after transplantation as
opposed to the mean follow-up here of 3.8 years. And their 
average age at transplant was 49, and the average age of 
onset of PVD was 56. 
So I would suggest that these patients harbor a genetic 
predisposition to very early development of both athero- 
genesis in the coronary artery beds with about 75% of these 
patients having received transplants for ischemic cardio- 
myopathy and premature development of PVD, because 
three of our 13 patients actually required peripheral 
vascular procedures before transplantation. 
We, of course, would expect hat the immunosuppres- 
sive regimen could also be atherogenic, with the rather 
malignant elevations of cholesterol, triglycerides, and 
blood glucose levels, which may accelerate he process. This 
emphasis, however, I think is an important point. 
In a high-risk population of heart ransplants, mokers, 
and ischemic ardiomyopathy, the risk of PVD is signifi- 
cant in these patients and needs to be carefully monitored, 
but there is a question as to whether this is cost-effective. 
The regimen described here is an expensive one, and these 
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patients are difficult to monitor. I would be interested in 
their thoughts, as regards cost/benefit analysis as they 
continue to monitor these patients. 
Second, we have had concerns with maintaining a
usable transplant service, regardless of whether we can still 
completely exclude all patients with PVD from transplan- 
tation. As a result, within the last 2 years there have been 
patients 'with some modest levels of PVD who have 
undergone heart transplantation. 
Last, I would just sort of ask for a gut feeling as regards 
to these two hypotheses. If you really do not believe that 
PVD exists in these patients and that maybe we just cannot 
measure it yet. 
Dr. Luke S. Erdoes. In response to the first statement 
about what were our exclusionary criteria, we used the 
same evaluation before transplantation asafter transplan- 
tation for excluding patients. If there was any evidence on 
the pretransplant screen of vascular disease, the patient was 
not considered for transplantation. 
We estimated the total extent of vascular disease by 
using our screening criteria. If any of the screening results 
were abnormal, we used traditional vascular testing to 
further delineate the vascular disease. That included seg- 
mental pressures, treadmill testing, arteriography, and 
duplex imaging as indicated. 
The question about progression versus acceleration of 
atherosclerosis n transplant recipients is an ongoing 
debate. The report by Julia and colleagues from France 
argued for progression, as did Dr. Mitchell. We believe that 
this is an accelerated process because of the fact that all of 
our patients were free of discernible vascular disease before 
the initiation of this study, and they all had this vascular 
disease within a relatively short follow-up interval, and 
their age is 10 to 15 years younger than that seen in the 
general population with atherosclerosis. It is certainly 
possible that these patients have a predisposition toward 
atherosclerosis; however, there is something in the immune 
rejection or immunosuppressive regimen that we feel is 
accelerating this process. 
The next question concerned the cost-effectiveness of 
vascular follow-up, and this is a vexing problem for us. In 
fact, our transplant team is in a financial bind as are others 
around the country, and there is some talk of trying to 
delete the vascular laboratory follow-up. Unfortunately, we 
cannot find one specific group that we can target our 
follow-up with. I think that this type of data is very 
appropriate to get, although it is expensive, and unfortu- 
nately, I cannot say how to decrease that expense. 
We, like the Stanford group, have begun accepting 
some patients with evidence of preexisting vascular disease 
and, in fact, in a very small cohort of patients we have 
repaired preexisting vascular lesions prior to transplanta- 
tion. Those patients have subsequently done well to date 
with their transplants. 
Now, the question of whether vascular disease exists 
before the transplant is impossible to answer by this study. 
I suspect that Dr. Mitchell is correct, that there is a 
predisposition i these patients, but as I stated earlier, I 
believe that something in the transplant milieu creates a 
rapid progression of this disease. 
Dr. Wiley F. Barker (Los Angeles, Calif.). It seems to 
me that the authors might profitably focus their attention 
on that group of patients who have received transplants 
because of nonischemic lesions such as viral cardiomyop- 
athy. In this group they might find better answers to the 
question as to whether peripheral arteriosclerosis arises de 
novo .  
Dr. Erdoes. Yes. We did not look specifically at the 
patients as separate groups with regards to other indica- 
tions for transplantation. However, all of those indications 
were placed in the logistic model, and none of them came 
out significant. Unfortunately, there are sporadic ases of 
posttransplant PVD developing in patients with non- 
ischemic indications for heart transplantation. 
Dr. J. Dennis Baker (Los Angeles, Calif.). I would 
question whether you have shown us proof that follow-up 
is indicated for peripheral occlusive disease. First of all, 
most cardiologists will work aggressively on risk factor 
modification. Patients are being pressed into smoking 
cessation and lipid reduction. I do not see that there is 
anything to be gained by documenting peripheral disease 
until it is symptomatic. 
The other thing I think you have to keep in mind also 
is that your screening criteria here are very insensitive to 
preexisting moderate disease. 
Dr. Erdoes. I agree with you that we may have some 
undetected isease present, and as I stated earlier, we 
cannot answer that question with this study. I think we 
have shown there to be a rapid progression after transplan- 
tation. 
As far as whether follow-up is indicated, we still feel it 
is for a variety of reasons. One is simply to learn more about 
these patients and try and discern why they get this 
problem, but in a more general sense it is very costly, and 
we have not identified specific risk factors but certainly the 
people who have noncompressible vessels, as a new 
observation, should be followed simply to get more data. 
I also think the follow-up in the carotid and aortic patients 
in particular can allow us to intervene prior to severe 
symptoms. 
The infrainguinal disease followed up with ankle/bran- 
chial indexes is probably the least expensive test we do. We 
are looking at doing some more specific duplex screening of 
wall thickness and scanning the entire superficial femoral 
artery. However, that is, of course, very costly, and we are 
trying to get grant money to fund this study. 
Dr. William C. Krupski (Denver, Colo.). Progression 
of occlusive disease in the coronary arteries after transplan- 
tation is a major problem, and several years ago in the New 
England Journal of Medicine it was reported that adminis- 
tration of calcium channel blockers to these patients helped 
prevent some acceleration ofatherosclerosis in the coronary 
circulation. I wonder if this is also true for peripheral 
vascular disease? 
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How many of your patients were on calcium channel 
blockers, and did this seem to ameliorate the changes that 
you have reported? 
Dr. Erdoes. That's a good question. The process in the 
coronary arteries appears to be different than in the" 
peripheral vessels. We studied the pathology of all plaques 
removed from our operated patients, and they were the 
garden-variety atherosclerotic plaque, as opposed to those 
in the coronary circulation where you have a concentric 
luminal narrowing, and it is believed to be an immune 
phenomenon. 
It is not certain if calcium channel blockers work by 
decreasing the blood pressure or by some other calcium- 
dependent mechanism or whether due to their immune 
suppressive effect. Most of our patients were treated with 
either angiotensin-converting e zyme inhibitors or calcium 
channel blockers, and we did not study the specifics of 
which patients received which antihypertensive drug. 
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